Cargando…

Association between Human Leukocyte Antigen and End-Stage Renal Disease in Patients from Transylvania, Romania

End-stage renal disease (ESRD) is the final stage of chronic kidney disease. This study explored the association between human leukocyte antigen (HLA) and ESRD. The interaction between genetic and environmental factors may also play a role in the development of ESRD. The study included 2392 ESRD pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Iancu Loga, Luminita-Ioana, Dican, Lucia, Chiorean, Alin Dan, Chelaru, Vlad Florin, Elec, Florin Ioan, Catana, Cristina Sorina, Marta, Monica Mihaela, Lucaciu, Roxana Liana, Hangan, Adriana Corina, Bondor, Cosmina Ioana, Vica, Mihaela Laura, Matei, Horea Vladi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488296/
https://www.ncbi.nlm.nih.gov/pubmed/37686189
http://dx.doi.org/10.3390/ijms241713383
Descripción
Sumario:End-stage renal disease (ESRD) is the final stage of chronic kidney disease. This study explored the association between human leukocyte antigen (HLA) and ESRD. The interaction between genetic and environmental factors may also play a role in the development of ESRD. The study included 2392 ESRD patients who were awaiting renal transplantation. Blood samples were genotyped by SSOP and SSP-PCR methods. Multivariate logistic regression analysis showed that HLA-A*11 (p = 0.027), HLA-A*34 (p = 0.017), HLA-A*69 (p = 0.012), HLA-B*41 (p < 0.001), HLA-B*50 (p = 0.004), HLA-DRB1*10 (p = 0.027), and HLA-DRB1*14 (p = 0.004) were positively associated with ESRD (OR > 1); HLA-DRB1*07 (p < 0.001), HLA-DRB1*08 (p = 0.005), and HLA-DRB1*13 (p < 0.001) were protective against ESRD (OR < 1); and the three-locus haplotype HLA-A*02–B*41–DRB1*03, containing one susceptible allele, was strongly associated with ESRD (p < 0.001, OR = 3.15). In conclusion, this retrospective analysis of HLA typing in patients with ESRD of various etiologies suggests that molecular data on the HLA polymorphism should be collected in order to identify high-risk ESRD patients and to improve graft survival after kidney transplantation.